Antibodies News and Research

RSS

Researchers identify link between autoimmune diseases, medications and Long QT syndrome

Mohamed Boutjdir, PhD, professor of medicine, cell biology, and physiology and pharmacology at SUNY Downstate Medical Center, has led a study with international collaborators identifying the mechanism by which patients with various autoimmune and connective tissue disorders may be at risk for life-threatening cardiac events if they take certain anti-histamine or anti-depressant medications.

7 Jul 2015

Blood-borne molecule promotes age-related cognitive decline

A blood-borne molecule that increases in abundance as we age blocks regeneration of brain cells and promotes cognitive decline, suggests a new study by researchers at UC San Francisco and Stanford School of Medicine.

7 Jul 2015

Study: New test may help predict effectiveness of biologic drugs in RA patients

A study of 311 patients by The University of Manchester has found that it may be possible to predict early which rheumatoid arthritis (RA) patients will fail to respond to the biologic drugs given to treat them.

3 Jul 2015

Imaging proteasome complex helps show target site for potential cancer drugs

Scientists have pioneered the use of a high-powered imaging technique to picture in exquisite detail one of the central proteins of life - a cellular recycling unit with a role in many diseases.

3 Jul 2015

Creating more effective vaccines against flu virus

Flu vaccines can be something of a shot in the dark. Not only must they be given yearly, there's no guarantee the strains against which they protect will be the ones circulating once the season arrives. New research by Rockefeller University scientists and their colleagues suggests it may be possible to harness a previously unknown mechanism within the immune system to create more effective and efficient vaccines against this ever-mutating virus.

3 Jul 2015

Research finding could lead to first effective therapies, vaccines against dengue virus

Researchers at Vanderbilt University and the National University of Singapore have determined the structure of a human monoclonal antibody which, in an animal model, strongly neutralizes a type of the potentially lethal dengue virus.

3 Jul 2015

Subcutaneous administration increases tolerability of multispecific antibody tumor treatment

Tumor treatment with multispecific antibodies is significantly more tolerable if administered subcutaneously rather than via the bloodstream, which was the standard procedure until now. This was the result of an animal model study undertaken by researchers at Helmholtz Zentrum München in cooperation with the Munich biotech company Trion Research.

1 Jul 2015

University of Oslo researchers find the cause of coeliac disease

Professor Ludvig M. Sollid and his colleagues at the University of Oslo have found the cause of coeliac disease. To do so required really going into depth, right down to molecular level.

1 Jul 2015

NIBIB-supported researchers create platelet-like particles to control excessive bleeding, augment clotting

NIBIB-supported researchers have created tiny gel particles that can perform the same essential functions as platelets. The particles could one day be used to control excessive bleeding following traumatic injury or in individuals with impaired clotting due to an inherited condition or as a result of certain medications or chemotherapy.

1 Jul 2015

CMC Biologics expands North American manufacturing facility with addition of Bioreactor 6Pack facility

CMC Biologics, Inc., a global leader in clinical and commercial manufacturing of monoclonal antibodies and other therapeutic proteins, announced today that, as part of its global manufacturing capacity expansion strategy, it has completed the expansion of its North American manufacturing facility in Bothell, Washington with the addition of a single-use Bioreactor 6Pack™ facility.

30 Jun 2015

Two antibodies show early promise in preventing and treating MERS

As the South Korean epidemic of Middle East Respiratory Syndrome (MERS) continues unabated, researchers have raced to find treatments for the deadly virus, which has killed more than 400 people since it was first discovered three years ago in Saudi Arabia.

30 Jun 2015

TSRI-led study identifies new immune molecules that protect against Marburg virus

A new study led by scientists at The Scripps Research Institute identifies new immune molecules that protect against deadly Marburg virus, a relative of Ebola virus. The research provides ingredients needed to develop treatments for future Marburg outbreaks.

30 Jun 2015

Clinical data demonstrates safe administration of Pexa-Vec in patients with metastatic colorectal cancer

SillaJen, Inc., a private clinical-stage biotherapeutics company focused on the development of oncolytic immunotherapy products for cancer, today announced a publication of data demonstrating that in a Phase Ib trial of Pexa-Vec, patients received multiple bi-weekly doses of its lead product Pexa-Vec, representing the first report of multiple intravenous administrations of an oncolytic vaccinia.

29 Jun 2015

Xencor announces progress and expansion of proprietary pipeline of XmAb antibodies

Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced updates on its lead product candidates, XmAb®5871 and XmAb®7195, and on its XmAb® bispecific oncology pipeline.

26 Jun 2015

New Christian Doppler Laboratory for Complement Research opens at MedUni Vienna

Today the new Christian Doppler Laboratory for Complement Research was opened at the Center for Pathophysiology, Infectiology and Immunology at MedUni Vienna. The research institute, which is funded by the Federal Ministry of Science, Research and Economic Affairs (BMWFW) is concentrating on a special protein that is thought to play an important role in controlling excessive immune reactions.

26 Jun 2015

Wistar Institute researchers identify specific mutations responsible for ineffectiveness of flu vaccines

Viruses like influenza have the ability to mutate over time, and given that the flu vaccines administered during the 2014-2015 season were largely ineffective at preventing the spread of the flu, it appears the virus that recently circulated had taken on mutations not accounted for when last year's vaccine was developed.

26 Jun 2015

MSD announces EC approval of SIMPONI (golimumab) for treatment of adult patients with nr-axial SpA

MSD (Merck & Co., Inc., Kenilworth, New Jersey, USA) today announced that on 22 June the European Commission approved SIMPONI (golimumab) for the treatment of adult patients with severe, active non-radiographic axial spondyloarthritis (nr-axial SpA).

26 Jun 2015

UC Santa Barbara professor develops novel therapeutic strategy for PKD

For the 12 million people worldwide who suffer from polycystic kidney disease (PKD), an inherited disorder with no known cure, a new treatment option may be on the horizon.

26 Jun 2015

Novasep to build fully integrated Antibody Drug Conjugate facility at Le Mans site in France

Novasep, a leading supplier of services and technologies for the life sciences industry, today announces it will build a fully integrated Antibody Drug Conjugate (ADC) facility at its Le Mans site in France. The new facility will enable Novasep to complement its current ADC offering with full bio-conjugation services to meet increasing market demand.

25 Jun 2015

UAlberta partnership could transform cancer treatment, improve patient outcomes

A multimillion dollar research partnership announced today at the University of Alberta is giving a "dream team" of researchers the opportunity to potentially transform cancer treatment and better patient outcomes.

25 Jun 2015

Antibodies News and Research

Researchers identify link between autoimmune diseases, medications and Long QT syndrome

Blood-borne molecule promotes age-related cognitive decline

Study: New test may help predict effectiveness of biologic drugs in RA patients

Imaging proteasome complex helps show target site for potential cancer drugs

Creating more effective vaccines against flu virus

Research finding could lead to first effective therapies, vaccines against dengue virus

Subcutaneous administration increases tolerability of multispecific antibody tumor treatment

University of Oslo researchers find the cause of coeliac disease

NIBIB-supported researchers create platelet-like particles to control excessive bleeding, augment clotting

CMC Biologics expands North American manufacturing facility with addition of Bioreactor 6Pack facility

Two antibodies show early promise in preventing and treating MERS

TSRI-led study identifies new immune molecules that protect against Marburg virus

Clinical data demonstrates safe administration of Pexa-Vec in patients with metastatic colorectal cancer

Xencor announces progress and expansion of proprietary pipeline of XmAb antibodies

New Christian Doppler Laboratory for Complement Research opens at MedUni Vienna

Wistar Institute researchers identify specific mutations responsible for ineffectiveness of flu vaccines

MSD announces EC approval of SIMPONI (golimumab) for treatment of adult patients with nr-axial SpA

UC Santa Barbara professor develops novel therapeutic strategy for PKD

Novasep to build fully integrated Antibody Drug Conjugate facility at Le Mans site in France

UAlberta partnership could transform cancer treatment, improve patient outcomes

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo